Clinical Trial Update: A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing SYN010 HFA inhaler with Symbicort 160/4.5 in healthy volunteers with charcoal block; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SYN010 HFA Inhaler
• Symbicort 160/4.5 (budesonide/formoterol)

Snippet

Sponsor: Intech Biopharm Ltd. | Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Status: COMPLETED